Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Inclusion Criteria: 1. Age: 18-75 years; 2. Hypopharyngeal squamous cell carcinoma confirmed by histopathology; 3. No distant metastases, stage III-IV (According to the 8th UICC/AJCC TNM staging system ); 4. At least 1 measurable lesion (according to RECIST1.1), and the lesion has not been treated; 5. Provide tissues for biomarker analysis; 6. ECOG PS 0-1; 7. Adequate hematologic, hepatic and renal function: ANC ≥ 1.5x10\^9/L, Hb ≥ 90g/L, PLT ≥ 100 x10\^9/L, albumin ≥ 28g/L, total bilirubin \< 1.5×ULN at diagnosis or after biliary drainage, ALT and AST \< 5×ULN, BUN、CREA\<1.5×ULN, creatinine clearance rate ≥ 45ml/min; 8. Contraception during the study; 9. At least 12 weeks of life expectancy; 10. Willing to join the study and sign informed consent. Exclusion Criteria: 1. Allergic to any component of carrelizumab, cisplatin and other platinum drugs; 2. Have received anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or CTLA-4 antibody therapy in the past; 3. Received biological treatment or participated in clinical trial of other drugs or devices within 4 weeks before enrollment; 4. Have other malignant tumors within 5 years, except for fully treated basal cell/squamous cell skin cancer/cervical cancer; 5. Have corticosteroids (\>10 mg prednisone equivalent dose per day) or other immunosuppressive agents for systemic treatment within 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergies, nausea or vomiting; 6. Uncontrolled clinical symptoms or diseases of the heart, such as: heart failure above NYHA II, unstable angina, myocardial infarction within 1 year； 7. Have severe infections (CTCAE\> Grade 2) occurred within 4 weeks before the first use of the study drug; 8. Have active autoimmune diseases, autoimmune diseases, but not including autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone; type 1 diabetes with stable doses of insulin; vitiligo or cured childhood asthma/allergies; 9. A history of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation; 10. A history of interstitial lung disease (excluding radiation pneumonia that has not been treated with hormones) and a history of non-infectious pneumonia; 11. Active tuberculosis, having antituberculosis therapy at present or within 1 year; 12. Have active hepatitis B (HBV DNA ≥2000 IU/mL or 10\~4 copies/mL) and hepatitis C; 13. Have other uncontrollable comorbidities; 14. Knowing a history of psychotropic drug abuse, alcohol or drug abuse; 15. Pregnant or breastfeeding, or expect to become pregnant during the clinical trial period.